Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Intocell is a biotechnology company that develops antibody drug conjugate (ADC) platform technologies.
Cimplrx is a health tech company focused on Drug Discovery.
ExoCoBio has been developing innovative therapeutics as well as cosmetic products based on stem cell-derived exosomes.
Atinum Partners has invested in 51 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Atinum Partners's top investment sectors include Biotechnology, Health Care, Information Technology, Medical, Therapeutics. The firm invests across 7 different industry categories.
Among tracked funding rounds, Intocell received $31.3M in a Series C round. Atinum Partners's total known invested capital is $412.9M.
Atinum Partners's average investment size is $11.5M across its portfolio of 51 companies.
Recent Atinum Partners portfolio additions include Intocell, Cimplrx, ExoCoBio. These companies were founded in 2020 or later.